Imaging Biometrics - Update and IB Nimble Webinar – 27 February 2026
Imaging Biometrics Limited
("IBAI" or the "Company")
Company Update
IB Nimble Webinar -
Imaging Biometrics Limited ('IBAI') comprises two subsidiary businesses, Imaging Biometrics LLC and Kirkstall Limited. In 2018, Imaging Biometrics, LLC ('IB') was acquired by Flying Brands Limited - now Imaging Biometrics Limited - and Kirkstall became part of the group in October last year.
In the subsequent eight years IB advanced several innovative technologies -including StoneChecker, LSN, and IB Zero G. Though substantial technical and developmental progress has been made over these years, it has not resulted in a concomitant commercial and revenue reward for shareholders. After considerable analysis we believe that this has been the consequence of pursuing too many projects with limited resources. One further consequence has been that we have invested less in the core legacy products that, in retrospect, we should have.
With the current market capitalisation of approximately
The last major release of IB Clinic, announced last fall, has seen initial adoption. Several existing clinical sites have upgraded to FTB Express processing, indicating interest in faster, more automated tumor-response metrics. Longitudinal reporting, identified as a useful quality enhancement by the neurosurgical community, will be added to improve the utility of IB Neuro and FTB maps. These updates further substantiate IB Clinic as the cornerstone of the product portfolio and position it for broader clinical adoption.
The next version of IB Nimble is nearing completion and includes integrated DICOM viewing, a feature requested by customers. This allows imaging data to be viewed directly within IB Nimble, facilitating the process from review to interpretation to clinical decision-making. To support this release and inform users, we will host a webinar on
QSMetric, the platform for producing FDA-cleared, patented quantitative susceptibility maps (QSM), has attracted initial interest. The system accepts data directly from MRI scanners and generates QSM maps using a proprietary algorithm. It is now being prepared for distribution to trial sites.
IB Zero G is a patented piece of intellectual property with potential long-term applications. However, advancing this technology requires significant resources and development time that affect focus on our primary products. In line with our strategy, IB Zero G will remain on hold until the Company's resources allow progress without impacting core business priorities.
IB played a central role in advancing the gallium maltolate (GaM) programme through the successful completion of its Phase 1 clinical trial; the results of which have now been submitted for publication. As previously communicated, the scope and scale of a Phase 2 trial would require resources beyond what IB can provide independently. While we are proud of the significant milestones achieved-including FDA Fast Track designation, two Rare Pediatric Disease designations, and two Orphan Drug Designations-the long‑term development pathway for GaM would divert focus and resources from the continued year‑over‑year growth of IB's core portfolio. For these reasons, we will not focus on advancing the programme at this time. We do have commercialisation rights to the Phase 1 trial data and will remain alert for potential commercial opportunities.
Kirkstall Limited: Driven by the growing adoption of the improved QV1200 system and the expansion of our international distribution network, sales were
In 2025 distributors were contracted in three strategically important markets:
Relevance of UK and US government policies
The
US agencies like FDA, EPA, and NIH promote "new approach methodologies" (NAMs). The FDA Modernization Act 2.0 (2022) allowed alternatives to animal testing for drugs, enabling sponsors to use methods such as cell-based assays and computer models rather than requiring animal studies. In
Customer Highlights
Gent University (
Blood-Brain Barrier Research:
Professor Cave and his team at Nottingham Trent University are developing next generation blood-brain barrier (BBB) organ on a chip system by combining their advanced nanofiber tissue scaffold inserts with Kirkstall's Quasi Vivo® platform to recreate realistic blood flow and neurovascular interactions. By growing the three key BBB cell types (endothelial cells, pericytes and astrocytes) inside the QV1200 system, which continuously circulates nutrients like real blood, the team has shown that the cells form stronger, intercellular connections and behave much more like they do in the human body. Importantly, the new scaffolds allow the cells to grow into their natural three-dimensional tissue structures, unlike conventional two-dimensional cell culture models where cells sit on flat plastic membranes without flow, limiting their physiological behavior. The QV1200 system's flowing, dynamic environment helps the BBB develop faster and far more effectively than older, static methods that lack real world physiological conditions. As a result, the platform offers a powerful, lifelike system for high throughput testing of new neurological treatments, enabling more reliable predictions of drug delivery and neuroprotective effects.
The Directors of the Company accept responsibility for the contents of this announcement.
For further information, please contact:
|
Imaging Biometrics Ltd Tel: 020 7469 0930 |
|
AlbR Capital Limited (Broker) Tel: 020 7220 9797 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE